Meridian Bioscience, Inc. Logo

Meridian Bioscience, Inc.

0K0K.L

(0.0)
Stock Price

33,97 USD

0% ROA

0% ROE

0x PER

Market Cap.

0,00 USD

0% DER

0% Yield

0% NPM

Meridian Bioscience, Inc. Stock Analysis

Meridian Bioscience, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Meridian Bioscience, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

Unidentified ROE

2 ROA

Unidentified ROA

3 PBV

Unidentified ROA

4 DER

Unidentified DER

5 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

6 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

7 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

8 Graham Number

Unidentified Graham Number

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Meridian Bioscience, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Meridian Bioscience, Inc. Technical Stock Analysis
# Analysis Recommendation

Meridian Bioscience, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Meridian Bioscience, Inc. Revenue
Year Revenue Growth

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Meridian Bioscience, Inc. Research and Development Expenses
Year Research and Development Expenses Growth

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Meridian Bioscience, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Meridian Bioscience, Inc. EBITDA
Year EBITDA Growth

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Meridian Bioscience, Inc. Gross Profit
Year Gross Profit Growth

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Meridian Bioscience, Inc. Net Profit
Year Net Profit Growth

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Meridian Bioscience, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Meridian Bioscience, Inc. Free Cashflow
Year Free Cashflow Growth

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Meridian Bioscience, Inc. Operating Cashflow
Year Operating Cashflow Growth

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Meridian Bioscience, Inc. Capital Expenditure
Year Capital Expenditure Growth

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Meridian Bioscience, Inc. Equity
Year Equity Growth

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Meridian Bioscience, Inc. Assets
Year Assets Growth

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Meridian Bioscience, Inc. Liabilities
Year Liabilities Growth

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Meridian Bioscience, Inc. Dividends
Year Dividends Growth
2018 0
2019 0 0%

Meridian Bioscience, Inc. Profile

About Meridian Bioscience, Inc.

Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H. pylori under the BreathID and BreathTek brand. This segment also offers respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry products for LeadCare test kits for the detection of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.

CEO
Mr. John P. Kenny
Employee
690
Address
3471 River Hills Drive
Cincinnati, 45244

Meridian Bioscience, Inc. Executives & BODs

Meridian Bioscience, Inc. Executives & BODs
# Name Age
1 Mr. Emerson C. Moser
Senior Vice President & Gen. Counsel
70
2 Ms. Julie Smith
Senior Vice President, Controller & Principal Accounting Officer
70
3 Mr. Jeff Pinkston
Director of Corporation Fin.
70
4 Ms. Susan D. Rolih
Consultant
70
5 Mr. Andrew S. Kitzmiller
Executive Vice President & Chief Financial Officer
70
6 Mr. Charles Wood
Vice President of Corporation Strategy, Bus. Devel. & Investor Relations
70
7 Ms. Melissa A. Lueke
Consultant
70
8 Dr. Lourdes G. Weltzien Ph.D.
Executive Vice President of Life Science Bus. Unit
70
9 Ms. Melissa J. McCarey
Vice President of Global HR
70
10 Mr. John P. Kenny
Pres, Chief Executive Officer & Director
70
11 Mr. Tony Serafini-Lamanna
Executive Vice President of Diagnostics
70

Meridian Bioscience, Inc. Competitors